'High base' impact: BYHEALTH’s Q1 sales suffer from lower demand for immune health products
China dietary supplement giant BYHEALTH reported a nearly 15 per cent slide in its Q1 revenue, which was mainly due to the reduced demand for immune health products as compared to the same time last year.